- $352.54m
- $363.38m
Brief: Cytodyn Inc - Exploring Leronlimab As A Potential Treatment For Patients Infected With 2019 Novel Coronavirus
Brief: Cytodyn Reports Early, But Strong Positive Clinical Responses For 2 Patients
Brief: Cytodyn Signs Agreements With Vyera Pharmaceuticals To Commercialize Leronlimab In The U.S.
Brief: Cytodyn Reports Strong Positive Preclinical Data To Demonstrate Potential Of Leronlimab
Brief: Cytodyn Appoints New Chief Financial Officer
Brief: Cytodyn Says First Patient In Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction In Circulating Tumor Cells
Brief: Cytodyn Inc Files For Offering Of 2.4 Million Shares Of Common Stock, Warrants To Purchase Up To 1.8 Million Shares Of Common Stock
Brief: Cytodyn Announces FDA Clearance To Proceed With Phase 2 Study Of Leronlimab And Regorafenib
Brief: Cytodyn Files An IND And A Phase 2 Protocol With The FDA For The Treatment Of NASH With Leronlimab
Brief: Cytodyn Inc Files Prospectus Relates To Offer, Sale By Selling Stockholders Of Up To 10 Million Shares Of Common Stock
Brief: Cytodyn Provides Update On Dose Escalating Trial With Leronlimab For Hiv Monotherapy For A Potential Pivotal Trial
Brief: Cytodyn Files A Phase 2 Protocol With The FDA For Leronlimab (PRO 140) And Regorafenib As A Combination Therapy For Metastatic Colorectal Cancer
Brief: Cytodyn Board Terminates Employment Of Richard Pestell, Co's Chief Medical Officer Effective Immediately
Brief: Cytodyn Finalizes Development Of Receptor Occupancy Test To Guide Pivotal Monotherapy Discussions With The FDA
Brief: CytoDyn Anticipates Revenue Commencing In August 2019 from Use of PA-14 and/or PRO 140 In Diagnostic Test
Brief: FDA Grants Face-To-Face Meeting To Discuss Cytodyn’S 510(K) Application For Prostagene Prognostic Test
Brief: Cytodyn And FDA Will Meet To Potentially Finalize Protocol For Pivotal Monotherapy Trial For Leronlimab
Brief: Samsung BioLogics: Size Of Order Could Grow To $240 Million Or More
Brief: CytoDyn And Samsung Biologics Formalize Manufacturing Partnership